- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Stephen Marmaras: Value and Co-Payment Assistance Programs
Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses value and patient co-payment assistance programs.
Transcript:
Are patient-assistance programs on the whole good or bad?
Well, we know that many of our community members rely on them to receive their therapy, so they’re very important. I think what is also important with patient-assistance programs is understanding that sometimes they can be abused. Our fear is that when they are abused, or when they’re used by individuals that may not actually need them, so to speak, it could compromise patient-assistance programs in general for the folks that are most vulnerable and need them.
I would point to a white paper that our organization did in collaboration with the University of Michigan [Center for Value-Based Insurance Design]. It looks at precision patient-assistance programs [and] how we can identify those vulnerable patients most at risk from a clinical standpoint and from a financial standpoint and making sure that co-pay assistance programs are available specifically to those individuals so that we can get people on the right treatment quickly.
I think it’s a balance. I think we need to be more responsible about applying co-pay assistance programs to individuals so that we can guarantee that they’ll be around for a longer period of time.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Empowering Vulnerable Populations: The Path to Equitable Biologic Therapy Access
December 22nd 2024Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, income-based cost sharing, patient assistance programs, and fostering payer partnerships.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Q&A With Dr Chelsee Jensen: Navigating FDA Approvals, Challenges in the Biosimilar Landscape
January 14th 2024Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, reacts to the biggest FDA approvals of 2023 and how she sees the adalimumab, natalizumab, and tocilizumab spaces playing out.
